NCI Council of Research Advocates Meeting on Immunotherapy Research

Event Dates: October 21, 2021

The NCI Council of Research Advocates (NCRA) meeting explores the cancer immunotherapy landscape with NCI Director Dr. Harold Varmus and other cancer research experts.  Topics to be discussed include therapeutic cancer vaccines, the role of adoptive T-cell therapy, regulatory advances in immunotherapy and ways advocates can advance cancer immunotherapy research. 

The NCRA, previously known as the Director’s Consumer Liaison Group (DCLG), is the only federal advisory committee comprised of advocate leaders at NCI. Max Wallace, CEO of Accelerate Brain Cancer Cure, is the chair of the group.  NCRA members are chosen for their expert knowledge of issues of importance to the cancer research community.

The NCRA focuses on matters that facilitate research and often identifies and responds to challenges facing the Institute at the request of NCI leadership. In addition, NCRA members bring their unique skills and perspectives by identifying new approaches, promoting innovation, recognizing unforeseen risks or barriers, and identifying unintended consequences that could result from NCI decisions. NCRA meetings are open to the public and focus on enhancing community input, optimizing community outreach, and promoting strong collaborations to improve research outcomes.

Information on past NCRA/DCLG meetings, including agendas and summaries, can be found through the NCI Division of Extramural Activities.

Share |

Join us in our fight for a cure!